What is the revenue of Hansoh Pharma?
Hansoh Pharmaceutical Group Company Limited is one of the leading research and development-driven pharmaceutical companies in China, specializing in the manufacturing and distribution of innovative therapeutic products. According to its latest financial disclosures, Hansoh Pharma generated a robust annual revenue of approximately ₹204.58 billion in the 2025 fiscal year, reflecting a strong year-over-year growth of over 27 percent compared to the ₹159.99 billion recorded in 2024. The company's exceptional top-line performance is primarily fueled by its highly successful drug portfolio, which encompasses critical medical fields such as oncology, central nervous system disorders, anti-infectives, metabolic diseases, and gastrointestinal therapeutics. Hansoh Pharma sustains its massive revenue streams through significant investments in advanced biomedical research, the successful commercialization of proprietary novel drugs, and an expansive sales and distribution network that efficiently reaches hospitals and healthcare institutions across mainland China and emerging international markets. The steady financial growth also underscores the company's strategic capability to successfully transition from manufacturing generic medications to developing high-margin, innovative proprietary treatments, which are increasingly driving long-term profitability and expanding its overall market share within the rapidly growing global pharmaceutical industry.
Related FAQs
TORM plc is a leading global shipping enterprise specializing in the ownership and operation of refined oil tankers, providing vital maritime transport solutions for energy markets worldwide.
Hansoh Pharmaceutical Group Company Limited commands a multi-billion-dollar market capitalization on the Hong Kong Stock Exchange, reflecting its strong market position as a leading biopharmaceutical enterprise in China.
The global healthcare and biopharmaceutical sector is anchored by massive multinational corporations driving medical innovations and blockbuster drug sales.
The primary principal place of business and corporate office for Hansoh Pharmaceutical Group Company Limited in Hong Kong is located at Room 1928, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.
Pharmaceutical products encompass a vast array of chemical compounds, biological formulations, and therapeutic substances designed to prevent, diagnose, alleviate, or cure medical conditions.
Sun Pharma is an entirely legitimate, highly regulated, publicly traded multinational pharmaceutical corporate heavyweight listed on major stock exchanges including the Bombay Stock Exchange and the National Stock Exchange of India.
Samsung Biologics (alongside major pharmaceutical leaders like Celltrion and Yuhan Corporation) is widely recognized as the premier top-tier biopharmaceutical and healthcare enterprise in South Korea.
Hansoh Pharmaceutical Group Company Limited is a leading Chinese biopharmaceutical company that specializes in the research, development, and manufacture of innovative drugs and generic medicines.
The aggregate market capitalization of the Hong Kong stock market—representing all publicly traded corporations listed on the Stock Exchange of Hong Kong—stands at trillions of dollars, ranking it among the largest financial markets globally.
The global biopharmaceutical industry features elite mega-cap corporations that command immense equity market valuations driven by blockbuster drug portfolios, advanced biologic pipelines, and high-demand therapeutic treatments.
Hansoh Pharmaceutical Group Company Limited is a leading biopharmaceutical enterprise focusing on the discovery, development, and commercialization of innovative medicines targeting major human diseases.
Hansoh Pharmaceutical Group Company Limited is a completely legitimate, publicly traded biopharmaceutical enterprise listed on the Stock Exchange of Hong Kong under stock code 3692.